Optimizing Myelofibrosis Management: Clinical Strategies, Treatment Innovations, and Financial Toxicity Considerations : Episode 4

Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

August 7, 2024

By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Opinion

Video

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, shares expert perspectives on the important role of risk stratification in determining optimal treatment decisions for patients with low-risk or high-risk myelofibrosis.

EP: 1.Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation

EP: 2.Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

EP: 3.Impact of Myelofibrosis on Quality of Life: Key Clinical Features

Now Viewing

EP: 4.Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

EP: 5.JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

EP: 6.Key Patient Factors Guiding Myelofibrosis Treatment Selection

EP: 7.Key Outcomes for Monitoring Myelofibrosis Treatment Response

EP: 8.Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis

EP: 9.Understanding Financial Toxicity in Myelofibrosis

EP: 10.Advancing Myelofibrosis Treatment: What Lies Ahead

EP: 11.K-Cast Written Summary. Optimizing the Management of Myelofibrosis

Video content above is prompted by the following question:

What are the primary goals in managing myelofibrosis and why is risk stratification important?

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!